Our contribution to UK healthcare

£2.4 billion – that’s equivalent to an extra 84,000 nurses taking care of patients

Or, with £2.4 billion the NHS could employ another 57,500 1^st year junior doctors

Or, an additional 34,500 GPs could be employed by the NHS with the £2.4 billion saved through prescribing and dispensing Teva’s generic medicines.

Collaborative working and joint working projects are specific types of partnership between the NHS and the pharmaceutical industry, which aim to improve the efficiency and delivery of patient care at a local level.

Teva’s collaborative and joint working projects put patient care, and innovation, right at their centre. Through the projects we combine skills, experience and / or resources from the NHS and industry to jointly develop and implement the initiative. Collaborative working really illustrates the way that Teva is able to be flexible and look at the needs of a particular patient population.

We have undertaken a number of collaborative and joint working initiatives with the NHS, along with a number of partnership working projects with NHS partners across the country.

They have focussed on working with the NHS in a transparent and open manner, supporting and implementing developments in healthcare delivery for the benefit of patients.

If you would like to learn more about our partnerships, please contact us.

Teva Runcorn employs around 500 people, working in a variety of highly skilled roles, ranging from quality assurance, manufacturing operations, research and development, engineering, microbiology and packaging.

The site develops a range of sterile liquid products for markets all around the world.

Developed in collaboration with patients, Life Effects™ offers information, insight and inspiration for people living with one or more chronic conditions.

It looks at how health and illness affects the lives of patients, and those around them, in a profound way that goes much further than the biology of illness and treatment.

Navigating the challenges and joys of caregiving: We also recognise the vital role of caregivers. Caregivers go to amazing lengths, embracing the challenges and demands of their changing role to bring care and joyous moments to a loved one as their health changes.

Within Life Effects™ we include advice on how to support a loved one with their ongoing health challenges, we also feature personal stories from caregivers that others may find reassuring and supportive.

With such a broad spectrum of therapy areas covered by our medicines range, we also have links with a number of charities and patient organisations and understand the value and role these important organisations play in supporting not only patients, but also their relatives and caregivers.

We actively encourage colleagues to volunteer for causes close to their hearts through our corporate volunteering initiatives.

A thriving life sciences industry in the UK means continued evolution and improvements in medicines, therapies and patient care.

We work with government, regulatory organisations, patient groups, trade associations and other key stakeholders to help them understand the work we do, the challenges we face and how the right policies and legislation can all work to improve the experiences patients have of their health and care here in the UK.

We’re proud of our UK-wide footprint, with our state-of-the-art distribution centre and head office located in Castleford, West Yorkshire, alongside our cutting-edge research and development and manufacturing facilities in Runcorn, Cheshire and Larne, Northern Ireland, supported by regulatory and commercial teams based in Harlow, Essex.

We’re passionate about delivering highly skilled roles and job opportunities to communities across the country.

From in-house innovation to strategic partnerships, we are persistently discovering, developing and delivering both generic and innovative medicines. We’re continually re-evaluating our generics and innovative medicines portfolios, pursuing new disease targets, novel treatments and biosimilars, as well as investing in our pipeline.

We aim to be at the forefront of biotech breakthrough, leveraging our unique collective knowledge to form global innovation consortia with groups from startups to patient organisation and the pharmaceutical industry with the goal of addressing unmet patient needs.

Getting a new medicine into the hands of patients can take a while. It’s a complex and expensive process.  At Teva we’re looking at new innovations such as ‘value-added medicines’, speciality generics and fixed dose combination products to meet the ever-evolving healthcare needs of the UK.

Take a deeper look at the development timeline for a medicine. On average, only one of every 10,000 promising substances will successfully pass testing in the R&D phase to be eventually approved as a marketable product. That means each molecule has a 0.1% chance of success! 02

We’re also investing in biopharmaceuticals as part of our long-term strategy for the future, and to help patients both in the UK and around the world. We’re focusing on treatments for the central nervous system, respiratory conditions, and in the field of oncology.

Biopharmaceuticals (also known as biologics) are complex medicines made from living cells or organisms. They advance more treatment options for patients, some of whom suffer from untreated or undertreated conditions. They have the potential to deliver precise and personalised treatment.